Posted by Michael Wonder on 16 Nov 2017
British Columbia and Prince Edward Island become the first provinces to add Erelzi (etanercept) to public drug plans for the treatment of multiple inflammatory diseases
16 November 2017 - Erelzi also becomes the first biosimilar indicated for polyarticular juvenile idiopathic arthritis under these provincial public drug plans.
British Columbia and Prince Edward Island are the first provinces to add Erelzi (etanercept) to their public drug plans for the treatment of multiple inflammatory diseases, respectively on November 14 and November 27. The two provincial listings follow the conclusion of an agreement between the pan-Canadian Pharmaceutical Alliance (pCPA) and Sandoz Canada, allowing member provincial, territorial and federal drug plans to fund this therapy for patients.
Erelzi, by Sandoz, a Novartis division and the pioneer and global leader in biosimilars, was granted Health Canada approval in April 2017 and was launched in Canada in August 2017.
